Eric Cantor to Lead PhRMA Amid Rising Pharma Scrutiny

Key points

• Cantor will assume the PhRMA presidency on November 9, succeeding Steve Ubl, who will remain as a strategic adviser until January 15, 2027.
• The role carries a salary of approximately $7.6 million, as reported by Politico, placing it at the top of the Washington trade group pay scale.
• PhRMA’s lobbying spending reached a record $38 million last year, a 22% increase from 2024, driven by policy pressures from the Trump administration and Congress.
• Cantor previously served as vice chairman and managing director at Moelis & Company since his 2014 primary defeat by tea party challenger Dave Brat.
• During his congressional tenure, Cantor helped build support for Medicare Part D and the 21st Century Cures Act, which expanded NIH funding and sped up FDA approvals.

Background

This appointment follows a period of significant disruption in the healthcare sector. The Trump administration has signed over two dozen deals with drugmakers to lower prices and avoid tariffs, while also questioning vaccine safety. Simultaneously, Congress is examining the industry’s business practices due to voter pressure on affordability. PhRMA’s previous leader, Steve Ubl, had a close relationship with the Republican party, but the current political landscape has shifted, with Democrats potentially regaining control of one chamber after the November midterms. Cantor’s background includes leading the Gabriella Miller Kids First Research Act and the 21st Century Cures Act during his time in Congress.

How outlets are covering it

Outlets highlight different aspects of the appointment. Politico emphasizes the financial scale of the role, noting Ubl’s $7.6 million salary, and the record-breaking lobbying spend. Axios focuses on Cantor’s age (63) and the potential challenge of facing rising scrutiny if Democrats take the House in the midterms. Fierce Pharma notes that Cantor will continue serving on Moelis & Company’s board and highlights the turbulent environment created by FDA changes under HHS Secretary Robert F. Kennedy Jr. STAT describes the appointment as a move to navigate a 'populist mood' from both parties regarding drug prices. There is a divergence in opinion on the hire: some, like Joel White of Monument Advocacy, praise Cantor’s business acumen and political savvy, while others, including a former Democratic staffer, criticize the choice as 'strange' given Cantor’s history of opposing Democrats and the changing relationship between pharma and the Republican party.

Why it matters

Cantor’s leadership of PhRMA signals a strategic pivot for the pharmaceutical industry as it navigates complex regulatory and political pressures. His experience in both high-level government and investment banking is seen as an asset for dealing with the Trump administration’s pricing deals and potential Democratic scrutiny. The appointment also reflects the industry’s need for a leader who can manage bipartisan tensions and advocate for patient access and AI-driven discovery in a highly polarized political environment.

What to watch

Cantor will officially begin his role on November 9. The pharmaceutical industry will continue to face scrutiny over pricing practices, with Democrats potentially investigating confidential pricing deals with the White House if they gain power in Congress. The confirmation process for new FDA commissioner Heidi Overton, M.D., is also ongoing, which may impact regulatory independence and industry relations.